Can-Fite BioPharma's CF102 is positioned as a second-line treatment for advanced hepatocellular carcinoma (HCC) in patients with Child-Pugh Class B cirrhosis. The market for HCC therapies is expanding, driven by increasing incidence rates and the need for effective treatments in advanced stages. CF102's unique mechanism targeting A3AR may provide a competitive edge over existing therapies. However, the competitive landscape includes established players with approved therapies, necessitating a robust demonstration of efficacy and safety to secure market share. Diligence should focus on the trial's outcomes, potential regulatory pathways, and reimbursement scenarios.